HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Perfusion lung scan as a prognostic indicator of response to beraprost sodium in idiopathic pulmonary arterial hypertension.

AbstractSTUDY OBJECTIVE:
To study whether there is any difference in the clinical characteristics between the two patterns of perfusion lung scan of idiopathic pulmonary arterial hypertension (normal vs. diffuse, multiple ill-defined defects) and whether the perfusion lung scan patterns of these patients would predict the effect of long-term use of beraprost sodium.
METHODS:
We evaluated 27 patients who used beraprost sodium for over 3 months, and noted a diffuse patchy pattern in 13 cases and a normal pattern in the remaining 14 cases. We judged that beraprost sodium was effective when at least two of the following conditions were met: improvement in symptom of dyspnea, more than 10% decrease in peak velocity of tricuspid valve regurgitation by echocardiography (Vmax), or more than 10% increase in 6-min walking distance.
RESULTS:
At baseline there was no difference between the two groups in dyspnea, hemodynamic parameters, and 6-min walking distance. After the use of beraprost sodium, the normal group showed improvement in dyspnea, 6-min walking distance, and Vmax. But the diffuse patchy group showed no improvement. The use of beraprost sodium in the normal group was effective in 10 out of 14 cases, but was effective in only two out of 13 cases in the diffuse patchy group.
CONCLUSION:
Perfusion lung scan pattern in patients with idiopathic pulmonary arterial hypertension is a useful prognostic indicator of the response to beraprost sodium.
AuthorsSo-Yeon Park, Dae-Hyuk Moon, Yong-Bum Park, Ju-Ok Na, Heong-Kon Whang, Byoung-Sung Lim, Sang-Do Lee
JournalPulmonary pharmacology & therapeutics (Pulm Pharmacol Ther) Vol. 19 Issue 4 Pg. 264-71 ( 2006) ISSN: 1094-5539 [Print] England
PMID16139536 (Publication Type: Journal Article)
Chemical References
  • Vasodilator Agents
  • beraprost
  • Epoprostenol
Topics
  • Adolescent
  • Adult
  • Blood Pressure (drug effects)
  • Cardiac Output (drug effects, physiology)
  • Dyspnea (diagnosis)
  • Echocardiography, Doppler
  • Epoprostenol (analogs & derivatives, pharmacology, therapeutic use)
  • Exercise Tolerance (drug effects)
  • Female
  • Humans
  • Hypertension, Pulmonary (diagnosis, drug therapy, etiology)
  • Lung (diagnostic imaging, pathology, physiopathology)
  • Male
  • Perfusion
  • Prognosis
  • Pulmonary Artery (drug effects, physiopathology)
  • Radionuclide Imaging
  • Treatment Outcome
  • Vascular Resistance (drug effects, physiology)
  • Vasodilator Agents (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: